AACR-NCI-EORTC Poster A010: Enhancing Syngeneic Immunogenicity through OVA Expression

Development of OVA-Expressing Immunogenic Syngeneic Mouse Tumor Models: CT26-OVA and B16-OVA

Ying Jin, Phillip Shuzong Wang, Zhongliang Li, Annie Xiaoyu An, Jiahua Zhou, Henry Qixiang Li, Davy Xuesong Ouyang

Syngeneics are the workhorse model for preclinical immunotherapy development. They do have drawbacks, however, including many models showing a lack of response to immune checkpoint inhibitors (ICI). This ICI-insensitivity could be due to the intrinsic low-/non-immunogenicity of these models.

To enhance immunogenicity, and provide new tools for I/O research, we’ve engineered syngeneic cell lines expressing the highly immunogenic protein ovalbumin (OVA). This poster details variants of the colon cancer CT26.WT and melanoma B16-F10 syngeneic models generated by introducing the OVA transgene.

Read this Poster to Discover:

• How OVA expression was confirmed via western blot for cells and by the presence of OVA specific antibodies in tumors
  
  
• That CT26-OVA and B16-OVA syngeneic models are more immunogenic than their parental cell lines, with enhanced anti-PD-1 therapeutic effect
  
  
• How ACT studies using CD3+ T cells from “cured” CT26-OVA tumor bearing mice following anti-PD-1 treatment confirmed the existence of long-lived memory CD8+ T cells

Download the Poster Now!